Carboplatin Paclitaxel in Ovarian Cancer
OncoPharm
00:00
Establishing the Current Backbone Regimen
John Bazar explains how this trial established carboplatin–paclitaxel every three weeks as the ovarian cancer standard.
Play episode from 08:35
Transcript
